When Johnson & Johnson scored approval for Tremfya inpsoriatic arthritis last year, the company set outin crowded field withentrenched competition. But now thedrugmakerhasnew long-term datato bolsterits drugs case.<\/p>\n
Indata from an extended phase 3 trial,more than half of adults on Tremfya achieved complete skin clearance at two years,J&J said. More than 70% of patients achieved 20% improvement or betterin joint symptoms.Previously, the drug showed benefits through 24 weeksleadingto an FDA approval last yearand through 52 weeks.<\/p>\n
Specifically, among patients who had experienced clinically meaningful skin involvement at baseline, 59% of patients who received Tremfya every four weeksand 53% of those who received the drug every eight weeksexperienced complete skin clearance, J&J said.<\/p>\n
About 90% of patients randomized toreceiveTremfya in the study continued their treatment through100 weeks, J&J said.Aside from the skin clearance and joint symptom effects, the two-year data confirmed earlierfindingsdemonstrating the meds benefits tophysical function and other quality-of-life factors, J&J said.<\/p>\n
The results further bolster our confidence in the ability of Tremfya to significantly improve the diverse manifestations ofPsAover time, Janssen R&D rheumatology disease area leader Alyssa Johnson said in a statement.<\/p>\n
RELATED:J&J's Tremfya grabs psoriatic arthritis nod, setting up a battle with Cosentyx, Taltz and more<\/p>\n
Investigators are presenting the data at theInnovations in Dermatology virtual spring meeting.<\/p>\n
The resultsgive J&Ja stepped-up talking point in a competitivefield. When Tremfya won itsFDA approval in psoriatic arthritis last year, the company set out to launch its drug against meds from AbbVie, Novartis and Eli Lilly. Plus, Lillys Taltz boastshead-to-head dataover the J&J drug.<\/p>\n
RELATED:Johnson & Johnson's Tremfya backs psoriatic arthritis play with newest data<\/p>\n
J&Js Tremfya, first approved inlate 2017 to treat plaque psoriasis,generated$1.35 billion last year.<\/p>\n
<\/p>\n
Follow this link: When Johnson & Johnson scored approval for Tremfya inpsoriatic arthritis last year, the company set outin crowded field withentrenched competition. But now thedrugmakerhasnew long-term datato bolsterits drugs case. Continue reading
\nChallenging AbbVie and Lilly in psoriatic arthritis, J&J touts 2-year data for Tremfya - FiercePharma<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"